BrightSpring Health Services, Inc. — Health Information Services. Scored on the same transparent 7-signal model behind the daily rankings.
★
BTSG
BrightSpring Health Services, Inc. · Health Information Services
FCF$412mC
Rev+28.2%A-
D/E1.36C
P/E91.8xD
PEG3.30D
49Score
$71.58$14.0B
1Y Target$67.00Analyst consensus · 16 analysts
5Y Target$98.09Compound horizon
10Y Target$145.52Long-dated conviction
FCF$412mTTMC
FCF $412m — modest; watch for margin expansion
Rev+28.2%TTM YoYA-
Revenue +28.2% — strong growth, well above S&P median (~7%)
D/E1.36C
D/E 1.36 — more levered than most Healthcare peers (≈90th pctile)
P/E91.8xD
P/E 91.8 — most expensive decile in Healthcare (≈95th pctile)
PEG3.30proxyD
PEG 3.30 — very expensive; pricing in best-case scenarios · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 49
Quality0.46
Growth1.00
Value0.26
Why this score
Diluting shareholders
Short track record
Entry · Margin of safety
52-week rangeNear 52-week high
1% off the 12-month high
vs DCF fair value140% aboveest. fair value ~$30
Quality signals · context only
ROIC6.5% · C+return on invested capital — not score-weighted
Why now
Health Information Services · market cap $14.0b. Trading near 52-week high of $72.06 — momentum setup, limited technical margin of safety. Revenue growing +28% — in hypergrowth territory. 16 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $67.00 (implying -6% upside).
Moat
ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 134% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trailing P/E 91.8x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Beta 1.79 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon
1-3 yr $67.00 (16-analyst consensus) — fundamentals + valuation re-rating. 5 yr $98.09 at ~7% CAGR — compounding case rests on the competitive position widening. 10 yr $145.52 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · BTSG
$
%
%
Shares to buy
27
Position size
$1,933
3.9% of portfolio
Stop price
$53.69
25% below $71.58
$ at risk if stopped
$483.16
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
BrightSpring Health Services, Inc. (BTSG): score, valuation & FAQ
BrightSpring Health Services, Inc. (BTSG) is a Health Information Services company that scores 49 out of 100 on the Bull Rankings quality-growth model — a below-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A-), while P/E (D) and PEG (D) rate weaker. On valuation, BTSG sits about 140% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich).
Is BTSG a good stock to buy?
Bull Rankings scores BTSG 49 out of 100 on its quality-growth model, which is a below-average reading. That is driven by Rev (A-). A score is a quantitative screen of BrightSpring Health Services, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does BTSG score 49 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). BTSG earns its highest marks on Rev (A-), and is held back by P/E (D) and PEG (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is BTSG overvalued or undervalued?
Based on $71.58, BTSG sits about 140% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich). It trades at a 91.8x× P/E (graded D). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in BTSG?
Trailing P/E 91.8x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Beta 1.79 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.